tirzepatide landmark trial for masld Tirzepatide- A novel therapeutic against metabolic dysfunction-associated steatotic liver disease (MASLD) SURPASS-CVOT trial results: Tirzepatide's impact

This initial dose sets the foundation for the treatment and ensures that the body can tolerate Zepbound (tirzepatide) effectively

The development of gut hormone dual- and triagonists holds promise for treating obesity and T2DM with a level of effectiveness comparable to bariatric surgery

Zepbound (tirzepatide) is FDA-approved for chronic weight management in eligible adults, providing a clinically studied option for sustained fat reduction

If you are having trouble with your pen jamming, our video may be able to help

Eur J Med Chem

Originally approved for type 2 diabetes, the diabetes drug Mounjaro not only treats diabetes but also aids in weight control, leading to its off-label use for obesity